Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech/OSI Tarceva Lung Cancer Trial Modified Following “Safety Signal”

Executive Summary

A "safety signal" detected during Genentech's Phase III trial of Tarceva (erlotinib) for first-line combination therapy in non-small cell lung cancer will not impact the rest of the agent's development program, the company said April 9

You may also be interested in...

Iressa User Fee Date Pushed To May; Will Advisory Cmte. Take Second Look?

FDA will take regulatory action on AstraZeneca's Iressa (gefitinib) by May 5

Iressa Cross-Over Study Could Show Clinical Benefit, AZ Says; ODAC Is Wary

AstraZeneca believes a controlled, cross-over trial could be used to confirm the sympom benefit of Iressa in refractory non-small cell lung cancer patients, VP-Medical Director of Oncology George Blackledge, MD, said during FDA's Oncologic Drugs Advisory Committee Sept. 24

Genentech/Novartis Xolair Indication Narrowed To Adult Allergic Asthma

Genentech and Novartis will seek a narrower label for the asthma biologic Xolair following the receipt of a "complete response" letter from FDA July 5.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts